


Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023
Updated safety and clinical efficacy data presented at leading…

Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia (FTD)
Vesper Bio, backed by Lundbeckfonden BioCapital, initiates…

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
New deal builds on encouraging preliminary clinical data…

Ariceum Therapeutics announces granting of US and Canadian patents for its Gallium-68 radiopharmaceutical production kit
Berlin, Germany, 6 December 2023 – Ariceum Therapeutics, a…

Versameb AG Names Dr. Alexandre LeBeaut as Chair of the Board of Directors
Versameb AG (“Versameb”), a pre-clinical stage company focused…

Sofinnova Partners unveils Sofinnova.AI: A cutting-edge artificial intelligence platform set to transform its life sciences investment practice
Combination of real time scientific databases with proprietary…

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer
Experienced, innovative biotech and pharma leader with demonstrated…

Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson’s Disease
Company on-track to dose first participant in multi-part,…

The first six companies enter the Deep Tech Lab – Quantum start-up accelerator at BII to unlock the potential in quantum science
BioInnovation Institute (BII), an international non-profit foundation…

Poolbeg Pharma plc – Directorate Change
30 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus
Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus”…

Kaleido launches cutting-edge Hybrid Closed Loop system with Diabeloop and Dexcom for people with diabetes
Kaleido is one of the world's…

Poolbeg Pharma – Immunomodulator II patent granted in Japan
21 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,…

Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK
SYNICEM™ hip, knee and shoulder spacers are preformed…

Poolbeg Pharma – POLB 001 LPS Challenge Trial Data to be Presented at IUIS
POLB 001 - a potential blockbuster immunomodulator
16 November…

Versameb Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence
Versameb AG (“Versameb”), a pre-clinical stage company focused…


IO Biotech Appoints Helen Collins, MD, to its Board of Directors
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s Disease
International research collaboration between Harvard Medical…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York